Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
The TRITON3 Study for mCRPC: Rucaparib or Physician's Choice?
Prostate cancer - The Lancet
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials - ScienceDirect
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC, Latest news for Doctors, Nurses and Pharmacists
Prostate cancer Nature Reviews Disease Primers
Rucaparib Bests Physician's Choice for BRCA+ mCRPC
Novel therapies are changing treatment paradigms in metastatic prostate cancer, Journal of Hematology & Oncology
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Management of Metastatic Castration-Resistant Prostate Cancer in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 5.5 (2021)
Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
